# F. Stephen Hodi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/f-stephen-hodi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 165,030 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 157 |
| i10-index | 507 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5084967339 |
| ORCID iD | https://orcid.org/0000-0001-6825-091X |
| Works | 1,559 |

## Researcher papers

Showing 12 of 17.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints](https://scholariq.org/papers/adaptive-resistance-to-therapeutic-pd-1-blockade-is-associated-with-upregulation/)
- [A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade](https://scholariq.org/papers/a-cancer-cell-program-promotes-t-cell-exclusion-and-resistance-to-checkpoint/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [Monitoring immune-checkpoint blockade: response evaluation and biomarker development](https://scholariq.org/papers/monitoring-immune-checkpoint-blockade-response-evaluation-and-biomarker/)
- [A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors](https://scholariq.org/papers/a-single-cell-and-single-nucleus-rna-seq-toolbox-for-fresh-and-frozen-human/)
- [Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer](https://scholariq.org/papers/incidence-of-programmed-cell-death-1-inhibitor-related-pneumonitis-in-patients/)
- [Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors](https://scholariq.org/papers/genomic-correlates-of-response-to-immune-checkpoint-blockade-in-microsatellite/)
- [Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors](https://scholariq.org/papers/clinicopathological-features-of-acute-kidney-injury-associated-with-immune/)
- [STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment](https://scholariq.org/papers/stk11-lkb1-deficiency-promotes-neutrophil-recruitment-and-proinflammatory/)
- [<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids](https://scholariq.org/papers/i-ex-vivo-i-profiling-of-pd-1-blockade-using-organotypic-tumor-spheroids/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.